A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Inclusion Criteria: * Patient must be 18 years or older with confirmed diagnosis of breast adenocarcinoma, colorectal carcinoma or non-small cell lung cancer * Patients must have relapsed or refractory disease following at least one chemotherapeutic treatment regimen. * Has a measurable, positron emission tomography (PET) assessable lesion * Adequate blood, liver, bone marrow and kidney functions * Has not received any chemotherapy for at least 4 weeks prior to entry in this study * Agrees to take adequate measures to prevent pregnancy. Exclusion Criteria: * Patient has had prior treatment with histone deacetylase (HDAC) inhibitor. * Patient has had treatment with investigational agents within the last 30 days. * Patient has active infection or had intravenous (IV) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs. * Patient has HIV, hepatitis B or hepatitis C infection. * Patient is pregnant or lactating. * Patient has allergy to any component of the study drug.